Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

National Immunization Strategy 2017-2022


Foreword
 
There have been many transformations to the NIP inthe recent years. New vaccines wereadded to the vaccination schedule, the cohorts served by the public sector kepton expandingsince the onset of the Syrian crisis, measures to consolidatethe vaccine purchasing arrangements were adopted,and there wasa leveraging up ofthe vaccinovigilanceand its effective management.In 2016, the Ministryof health in Lebanon decided that it was the time to take stock, constructon the current NIP strengthsand achievements andidentify areas for further improvement. A strategy for the NIP for 2016-2020 wasenvisagedin agreementwith the development partners. A detailed situation analysis assessment was initiatedin October 2015 in two stages: at the initial stage, the country and health system contexts were analyzed, and immunization system performance was measured. In the second stage, a framework was developed in consultations with key stakeholders to define gaps in the evidence. Immunization coverage evaluation survey was conducted in 2016 and fed into filling the lacunas in information.

The present document expresses the country vision, goals and priorities of the national immunization program. It relies on a careful examination of the situation analysis, an assessment of the enablers and challenges facing the immunization services and defines the national immunization strategies addressing these contests. The strategies were formulated as informed choices across more than one solution deemed most feasible and efficient considering the country context.

The document is structured in three sections:

Section 1“Situational analysis” presents briefly the organization and operation of the national immunization program as well as the recent achievements and remaining challenges,

Section 2 “Conceptual framework” describes the future vision of the country in regards to vaccine preventable diseases, the long term goals to be achieved and the more specific results –immunization system objectives and targets for 2020,

Section 3 defines the Strategies to address the bottlenecks and achieve immunization system objectives by 2020. Most of strategies (so called “immunization system specific” ones) are presented by relevant health system blocks.The focus of the NIP Strategy, is to assistthe MOPH to meet international goals set by the World Health Organization (WHO) under the Global Immunization Vision and Strategy (GIVS). The Strategy articulates action areas to conserve the successful achievements of the last years, built on the current favoring momentum and propose solutions for the drawbacks

The Strategy comprises nineStrategic Priority Areas to complement and strengthen the NIP.

The matrix (Figure 2) in Annexesshows expected results of the immunization system development strategies by health system building blocks and links them to the root causes (weaknesses and treats) identified during the system analysis...
    ...
    40
    ...
ATC Name B/G Ingredients Dosage Form Price
D10BA01 CURACNE G Isotretinoin - 10mg 10mg Capsule, soft gelatin 970,254 L.L
G04CA02 TALUSIN G Tamsulosin HCl - 0.4mg 0.4mg Capsule, modified release 683,440 L.L
J01DD01 STOPAREN G Cefotaxime (sodium) - 1g 1g Injectable lyophilised powder for solution+diluent 213,671 L.L
L01AX03 TEGOZOL G Temozolomide - 100mg 100mg Capsule 5,012,533 L.L
M01AH05 COXIFLAM G Etoricoxib - 90mg 90mg Tablet, film coated 1,293,928 L.L
N02BE01 PARA-DENK 125 SUPPOS. G Paracetamol - 125mg 125mg Suppository 190,826 L.L
N05AE05 LURABIL G Lurasidone - 20mg 20mg Tablet, film coated 2,535,831 L.L
N06AX21 PMS-DULOXETINE G Duloxetine HCl - 30mg 30mg Capsule, delayed release 642,357 L.L
S01AE07 AROX G Moxifloxacin (HCl) - 0.5% 0.5% Drops 423,310 L.L
A02BC04 RAZOLE 20 G Rabeprazole sodium - 20mg 20mg Tablet, enteric coated 282,847 L.L
A11CC05 ALTUM G Vitamin D3 - 50,000IU 50,000IU Capsule, hard 712,620 L.L
B03AC FER PANPHARMA G Iron (sucrose) - 100mg/5ml 100mg/5ml Injectable solution 2,315,441 L.L
C10AA07 UBSATOR-CA G Rosuvastatin (calcium) - 20mg 20mg Tablet, film coated 499,142 L.L
D10BA01 A-CNOTREN G Isotretinoin - 20mg 20mg Capsule, soft gelatin 1,468,376 L.L
G04CA02 TAMSU GENERICON RETARD G Tamsulosin - 0.4mg 0.4mg Capsule, hard, modified release 615,480 L.L
J01DD02 CEFTAZIDIME PANPHARMA G Ceftazidime (pentahydrate) - 1g 1g Injectable powder for solution 3,300,477 L.L
L01AX03 TEMOZOLOMIDE ACCORD G Temozolomide - 100mg 100mg Capsule, hard 5,590,385 L.L
M01AH05 ETOXA G Etoricoxib - 90mg 90mg Tablet, film coated 1,293,928 L.L
N02BE01 SULDEX 125 G Paracetamol - 125mg 125mg Suppository 110,067 L.L
N05AE05 LAROZA G Lurasidone - 40mg 40mg Tablet, film coated 5,548,726 L.L
N06AX21 DULOXETINE BIOGARAN G Duloxetine HCl - 60mg 60mg Capsule, gastro-resistant 573,821 L.L
S01AE07 FORTYMOX G Moxifloxacin (HCl) - 0.5% 0.5% Drops solution 772,709 L.L
A02BC04 RAZOLE 20 G Rabeprazole sodium - 20mg 20mg Tablet, enteric coated 639,925 L.L
A11CC05 BIODAL G Vitamin D3 - 50,000IU 50,000IU Tablet, film coated 1,110,014 L.L
B03AC FER PANPHARMA G Iron (sucrose) - 100mg/5ml 100mg/5ml Injectable solution 2,315,441 L.L
C09CA08 OLMENOR G Olmesartan medoxomil - 10mg 10mg Tablet, film coated 526,786 L.L
D10BA01 CONTRACNE ISOTRETINOINE G Isotretinoin - 20mg 20mg Capsule, soft 1,521,230 L.L
J01DD02 FORTECARE G Ceftazidime - 1g 1g Injectable powder for solution 10,011,695 L.L
L01AX03 TEMOZOLOMIDE GP PHARM G Temozolomide - 100mg 100mg Capsule, hard 4,511,279 L.L
M01AH05 ETOXA G Etoricoxib - 90mg 90mg Tablet, film coated 431,309 L.L
    ...
    40
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025